Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
Daily notebook from the J.P. Morgan Healthcare conference: Novartis says Kisqali will be its biggest drug yet; BMS reports strong launch for Cobenfy; Sarepta talks plans for building on Elevidys's success; Lilly updates guidance as tirzepatide slips; and GSK's Miels worked overtime on IDRx.
Daily notebook from the J.P. Morgan Healthcare Conference: J&J's Duato talks about Intra-Cellular deal; GSK's Wood explains how IDRx fits its BD strategy; and Senator Burr says industry needs to look at the long term.
Industry should take a long-term view on policy issues, the former Republican legislator told biopharma execs at the J.P. Morgan Healthcare Conference.
The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).
GSK will pay up to $1.15bn for IDRx, Lilly is said to be making a play for Scorpion, Biogen offered to buy Sage and Gilead announced a partnership with Leo Pharma ahead of the J.P. Morgan Healthcare Conference.
The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.